Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138578 | 0.81 | GAA (0.46) | GAAMGAMSIMGAM2ATM | |
| SCHEMBL5228548 | 0.79 | EPHX1 (0.48) | ATMALDH1A1 | |
| SCHEMBL5639931 | 0.79 | GAA (0.46) | GAAMGAMSIMGAM2ATM | |
| SCHEMBL3836989 | 0.79 | GAA (0.44) | GAAMGAMSIMGAM2SMN1; SMN2 | |
| SCHEMBL9574919 | 0.79 | GAA (0.44) | GAAMGAMSIMGAM2ATM | |
| SCHEMBL23928061 | 0.77 | GAA (0.42) | GAAMGAMSIMGAM2ATM | |
| SCHEMBL530163 | 0.77 | FNTA (0.46) | GAAMGAMSIMGAM2SMN1; SMN2 | |
| SCHEMBL25961960 | 0.77 | GAA (0.42) | GAAMGAMSIMGAM2SMN1; SMN2 | |
| SCHEMBL530162 | 0.77 | GAA (0.42) | GAAMGAMSIMGAM2ATM | |
| SCHEMBL21420125 | 0.77 | ATM (0.39) | GAAMGAMSIMGAM2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319305-B2 | Pyrimidine sulfamide derivative and preparation method and medical application thereof | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| CN-107427527-B | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | 英安塔制药有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-20200283425-A1 | PYRIMIDINE SULFAMIDE DERIVATIVE AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | Wuxi Biocity Biopharmaceutics Co., Ltd. (CN) | 2020-09-10 | — | — | US | disclosed |
| EP-2598556-B1 | PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS | WACKER CHEMIE AG (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8741979-B2 | Process for producing siloxane copolymers with urethane-sulphonamido linking groups | WACKER CHEMIE AG (DE) | 2014-06-03 | — | — | US | disclosed |
| EP-2598556-A1 | PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS | Wacker Chemie AG (DE) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123376-A1 | PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS | WACKER CHEMIE AG (DE) | 2013-05-16 | — | — | US | disclosed |
| WO-2012013558-A1 | PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS | WACKER CHEMIE AG (DE) | 2012-02-02 | — | — | WO | disclosed |
| EP-0614887-B1 | Indole-sulfonamides as antitumor agents | LILLY CO ELI (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5565494-A | BENZENESULFONYLUREA DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1994020101-A1 | ANTITUMOR COMPOSITIONS AND METHODS OF TREATMENT | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
| EP-0614887-A1 | Indole-sulfonamides as antitumor agents | ELI LILLY AND COMPANY (US) | 1994-09-14 | — | — | EP | disclosed |
| EP-0602878-A1 | Diarylsulfonylureas and their use as antitumor agents | ELI LILLY AND COMPANY (US) | 1994-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123376-A1 | PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS | STS, MPST, IDUA | GAA 288/4885MGAM 175/4885SI 16/4885 |
| US-11319305-B2 | Pyrimidine sulfamide derivative and preparation method and medical application thereof | TBXA2R, P2RY11, TPMT | GAA 2188/4885MGAM 3101/4885SI 864/4885 |
| US-20200283425-A1 | PYRIMIDINE SULFAMIDE DERIVATIVE AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | TBXA2R, P2RY11, TPMT | GAA 2188/4885MGAM 3101/4885SI 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.